| The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer A Afshar-Oromieh, E Avtzi, FL Giesel, T Holland-Letz, HG Linhart, M Eder, ... European journal of nuclear medicine and molecular imaging 42, 197-209, 2015 | 1108 | 2015 |
| 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer C Kratochwil, F Bruchertseifer, FL Giesel, M Weis, FA Verburg, F Mottaghy, ... Journal of Nuclear Medicine 57 (12), 1941-1944, 2016 | 956 | 2016 |
| 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 WP Fendler, M Eiber, M Beheshti, J Bomanji, F Ceci, S Cho, F Giesel, ... European journal of nuclear medicine and molecular imaging 44, 1014-1024, 2017 | 755 | 2017 |
| PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617 C Kratochwil, FL Giesel, M Stefanova, M Benešová, M Bronzel, ... Journal of Nuclear Medicine 57 (8), 1170-1176, 2016 | 626 | 2016 |
| Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer M Benešová, M Schäfer, U Bauder-Wüst, A Afshar-Oromieh, C Kratochwil, ... Journal of Nuclear Medicine 56 (6), 914-920, 2015 | 596 | 2015 |
| F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients FL Giesel, B Hadaschik, J Cardinale, J Radtke, M Vinsensia, W Lehnert, ... European journal of nuclear medicine and molecular imaging 44, 678-688, 2017 | 556 | 2017 |
| Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients A Afshar-Oromieh, T Holland-Letz, FL Giesel, C Kratochwil, W Mier, ... European journal of nuclear medicine and molecular imaging 44, 1258-1268, 2017 | 535 | 2017 |
| Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer M Eder, O Neels, M Müller, U Bauder-Wüst, Y Remde, M Schäfer, ... Pharmaceuticals 7 (7), 779-796, 2014 | 449 | 2014 |
| The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions A Afshar-Oromieh, H Hetzheim, C Kratochwil, M Benesova, M Eder, ... Journal of Nuclear Medicine 56 (11), 1697-1705, 2015 | 423 | 2015 |
| Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy CM Zechmann, A Afshar-Oromieh, T Armor, JB Stubbs, W Mier, ... European journal of nuclear medicine and molecular imaging 41, 1280-1292, 2014 | 421 | 2014 |
| Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer A Delker, WP Fendler, C Kratochwil, A Brunegraf, A Gosewisch, ... European journal of nuclear medicine and molecular imaging 43, 42-51, 2016 | 334 | 2016 |
| EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) C Kratochwil, WP Fendler, M Eiber, R Baum, MF Bozkurt, J Czernin, ... European journal of nuclear medicine and molecular imaging 46, 2536-2544, 2019 | 326 | 2019 |
| Detection efficacy of 18F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy FL Giesel, K Knorr, F Spohn, L Will, T Maurer, P Flechsig, O Neels, ... Journal of Nuclear Medicine 60 (3), 362-368, 2019 | 326 | 2019 |
| Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy U Hennrich, K Kopka Pharmaceuticals 12 (3), 114, 2019 | 286 | 2019 |
| Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo M Schäfers, B Riemann, K Kopka, HJ Breyholz, S Wagner, ... Circulation 109 (21), 2554-2559, 2004 | 270 | 2004 |
| The rise of PSMA ligands for diagnosis and therapy of prostate cancer A Afshar-Oromieh, JW Babich, C Kratochwil, FL Giesel, M Eisenhut, ... Journal of Nuclear Medicine 57 (Supplement 3), 79S-89S, 2016 | 255 | 2016 |
| Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging J Cardinale, M Schäfer, M Benešová, U Bauder-Wüst, K Leotta, M Eder, ... Journal of Nuclear Medicine 58 (3), 425-431, 2017 | 248 | 2017 |
| 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients F Sterzing, C Kratochwil, H Fiedler, S Katayama, G Habl, K Kopka, ... European journal of nuclear medicine and molecular imaging 43, 34-41, 2016 | 240 | 2016 |
| [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer C Kratochwil, FL Giesel, M Eder, A Afshar-Oromieh, M Benešová, W Mier, ... European Journal of Nuclear Medicine and Molecular Imaging 42, 987-988, 2015 | 206 | 2015 |
| Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors M Benesova, U Bauder-Wüst, M Schäfer, KD Klika, W Mier, ... Journal of Medicinal Chemistry 59 (5), 1761-1775, 2016 | 205 | 2016 |
Michael SchäfersProfessor of Nuclear Medicine and Molecular Imaging, University of MünsterBestätigte E-Mail-Adresse bei uni-muenster.de
